Natera, Inc. (NTRA)
| Market Cap | 10.21B |
| Revenue (ttm) | 449.31M |
| Net Income (ttm) | -258.23M |
| Shares Out | 87.94M |
| EPS (ttm) | -3.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $119.66 |
| Previous Close | $114.96 |
| Change ($) | 4.70 |
| Change (%) | 4.09% |
| Day's Open | 115.25 |
| Day's Range | 115.25 - 119.90 |
| Day's Volume | 1,023,230 |
| 52-Week Range | 44.57 - 127.19 |
AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd. , (300676.SZ), one...
AUSTIN, Texas, June 18, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS) ha...
AUSTIN, Texas, June 16, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ab...
CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracke...
AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific i...
Naturally Splendid Enterprises Ltd (FRA:50N) (CVE:NSP) (OTCPINK:NSPDF) has reported its first-quarter results, revealing a narrowing loss compared to the same period of 2020. The company's net loss was ...
AUSTIN, Texas, May 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt ...
AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced initial results from the CIRCULATE-Japan trial, the largest...
Natera (NTRA) delivered earnings and revenue surprises of 29.52% and 31.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.44% over the past year to ($0.74), which beat the estimate...
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2021...
AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present 4 posters at the 2021 American Society of C...
Naturally Splendid appoints CANEX Foods as master distributor for NATERA Plant Based Foods in Canada
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N) has appointed CANEX Foods as master distributor for NATERA Plant Based Foods in Canada. Previously, CANEX Foods was a distributor ...
AUSTIN, Texas, April 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its first quarter ende...
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N) has announced that the third shipping container of Natera Plant Based Foods has arrived from Australia. In anticipation of demand ...
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N) has announced that the third shipping container of Natera Plant Based Foods has arrived from Australia. In anticipation of demand ...
AUSTIN, Texas, April 22, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and a global leader in cell-free DNA testing, receives pathway to future coverage for the Prospera donor-derived, c...
The stock price of Natera, a clinical genetic testing company, has seen a large 14% drop in just five trading sessions. The decline is driven in part by the broader sell-off in high growth stocks, and p...
AUSTIN, Texas, April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has implemented the first wave of Panorama AI innovations following the br...
These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.
AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs, a US multi-region lab servic...
AUSTIN, Texas, March 24, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the US Food and Drug Administration (FDA) has grante...
AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the first patient has been screened in a new phase ...
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N), a supplier of vegetarian meat substitutes, sports and energy bars, and hemp-based products, has appealed the Federal Court of Cana...
Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 93.48% year over year to ($0.89), which missed the estimate o...
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $NTRA #PrecisionOncology--Natera and Personalis Partner for Personalized Monitoring in Oncology
SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy M...
SAN CARLOS, Calif., Jan. 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-owned subs...
SAN CARLOS, Calif., Jan. 14, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Prospera test...
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumo...
These winners are positioned for gains even after COVID.
SAN CARLOS, Calif., Jan. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 39th A...
SAN CARLOS, Calif., Dec. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Nater...
Increased adoption and expansion of products resulting in significant rises in volume. Producing meaningful improvements in revenues and costs per unit.
SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has ...
SAN CARLOS, Calif., Nov. 30, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of Oncology, highlight...
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.
SAN CARLOS, Calif., Nov. 12, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord ...
In this article we will take a look at whether hedge funds think Natera Inc (NASDAQ:NTRA) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours...
SAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its persona...
Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call Transcript
Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN CARLOS, Calif., Oct. 30, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal Diagno...
SAN CARLOS, Calif., Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter en...
SAN CARLOS, Calif., Oct. 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that a major health plan has extended coverage for no...
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fert... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 2, 2015 |
| Stock Exchange NASDAQ | Ticker Symbol NTRA |
Financial Performance
In 2020, Natera's revenue was $391.01 million, an increase of 29.33% compared to the previous year's $302.33 million. Losses were -$229.74 million, 84.0% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for Natera stock is "Strong Buy." The 12-month stock price forecast is 137.00, which is an increase of 14.49% from the latest price.